$A phase 1a clinical trial of LYM-1 monoclonal antibody serotherapy in patients with refractory b cell malignancies$

A phase 1a clinical trial of LYM-1 monoclonal antibody serotherapy in patients with refractory b cell malignancies

Ten patients with refractory B cell lymphomas were treated with weekly intravenous infusions of escalating doses of murine monoclonal antibody (MoAb) LYM‐1 over four weeks. LYM‐1 is a recently developed IgG2a murine MoAb that recognizes a polymorphic HLA‐Dr antigen on surfaces of normal and malignan...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Hematological oncology 1989-03, Vol.7 (2), p.155-166
Hauptverfasser:	Hu, Eddie, Epstein, Alan L., Naeve, Gregory S., Gill, Indraini, Martin, Sue, Sherrod, Andy, Nichols, Peter, Chen, David, Mazumder, Amitabha, Levine, Alexandra M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - immunology Antibodies, Monoclonal - therapeutic use B-Lymphocytes Biological and medical sciences Cytotoxicity, Immunologic Female Hematologic and hematopoietic diseases HLA-DR Antigens - immunology Humans Immunization, Passive Immunoglobulins - analysis Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Leukocyte Count LYM-1 lymphoma Lymphoma - therapy Male Medical sciences Middle Aged monoclonal antibody
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!